Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 15, 2023
Discovery & Translation

GDF15 linked to severe nausea in pregnancy; plus Carvykti mechanism and more

BioCentury’s roundup of translational innovations
BioCentury | Oct 26, 2018
Tools & Techniques

Deconstructing the rule of five

The last 20 years of drugs undermines the relevance of the rule of five
BioCentury | Jul 17, 2018
Financial News

CanSino latest to file for HKEX IPO

BioCentury | Jul 17, 2018
Financial News

CanSino latest to file for HKEX IPO

BioCentury | Jun 15, 2018
Clinical News

Chinese approval for Ascletis' HCV drug

BioCentury | Jun 13, 2018
Company News

Chinese approval for Ascletis' HCV drug

BioCentury | May 25, 2018
Finance

HKEX’s on-demand experts

How HKEX plans to leverage its biotech advisory panel
Items per page:
1 - 10 of 300